Notícias

The S&P 500 and Nasdaq rose slightly Wednesday as Treasury yields fell. Moderna and Merck fueled big gains for biotechs, drugmakers.

The stock has stood out while the index has barely moved, but the number that matters for a portfolio is how little of its return comes from the market.

AbbVie's upside case now turns on one pending dosing change for the medicine that supplies close to a third of guided revenue, and management expects it to speed up sales.

Novo Nordisk stock has fallen sharply over the past three years, yet the broader valuation checks still flag it as looking cheap rather than stretched. Recent headlines around obesity treatments, intellectual property protection and a large buyback programme add extra context to whether that discount is justified. The share price has declined 49.9% over the past three years, which suggests many investors have already reset their expectations for the stock. Growth expectations around GLP-1...

OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.

Lilly, Novo, and Merck have each priced in a radically different version of the next two years, and one of them looks like a setup where the market has it badly wrong.

Eli Lilly's GLP-1 portfolio outpaces its rival in Q2, while Foundayo gains momentum and can challenge Wegovy's early oral obesity lead.

PFE aims to break into the obesity market with berobenatide, a potential monthly treatment designed to compete with leading GLP-1 therapies.

ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory backing and a 2029 readout ahead.

Franklin Biotechnology Discovery has a much higher 13% five-year annualized return than a biotech index ETF’s 5.3%

Eli Lilly just became the first pharmaceutical company ever valued above $1 trillion, yet analysts who dig into its pipeline are arguing the market still has not grasped what the next two years could look like for shareholders.

A clinical-stage radiopharmaceutical startup with no product revenue just caught the attention of three of pharma's biggest acquirers, and the rights structure hiding inside its Lilly partnership may explain exactly why.

Stock Market Today: The Dow Jones index rises Wednesday ahead of the Fed minutes. Nvidia supplier SK Hynix jumps on a stock buyback.

The weight-loss pills battle between Eli Lilly and Novo Nordisk could add to the projected $200 billion market for obesity drugs.

Pharmaceutical chiefs are always hunting for drugs to replace expiring blockbusters. But shopping while hungry can lead to expensive mistakes.

As Eli Lilly and Novo Nordisk race for share, surveys show affordability and prescribing preferences may help decide the winners.

Franklin Biotechnology Discovery has a much higher 13% five-year annualized return than a biotech index ETF’s 5.3%

UnitedHealth Group Incorporated (NYSE:UNH) and Eli Lilly and Company (NYSE:LLY) both have respectable dividend records, but the two companies are at different stages of their dividend journeys. UNH has the longer history. It has paid dividends since 1990 and has raised its payout for 16 straight years. Its quarterly dividend now stands at $2.32 per […]

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the company announced two deals, acquiring rights to a preclinical Alzheimer's drug and entering a collaboration for an ion channel program.

Eli Lilly (NYSE: LLY) announced new global collaborations focused on ion channel drug discovery with OmniAb and a trial partnership with Amplia Therapeutics in KRAS G12C-mutant lung cancer. The OmniAb agreement centers on applying its ion channel platform to Eli Lilly's neuroscience research pipeline. The Amplia collaboration targets a clinical trial program that combines FAK and KRAS G12C-directed therapies for lung cancer patients. These deals expand Eli Lilly's external R&D partnerships...

Sandisk, Micron, Credo and many other chip and AI stocks dived a day after bullish moves. The major indexes are wiping out recent gains.

Lilly rises as Mounjaro and Zepbound fuel record growth, while GuruFocus shows shares below estimated fair value.

The safest Vanguard funds can help you through a volatile market by adding stability to your portfolio at low cost.

OPK raises $125 million against mazdutide royalties, gaining non-dilutive capital while retaining longer-term royalty upside.

Eli Lilly is Tuesday's IBD Stock Of The Day. Shares are staring down two potential entries as the weight-loss kingpin gains on Novo Nordisk.

Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to make a move before pivotal trial data arrives.

J&J's immunology and neuroscience businesses are emerging as key growth engines, with new drugs helping to offset Stelara's loss of exclusivity.

Proceeds from the investment will enable Leal Therapeutics to proceed with an initial data readout from LTX-001.

Can Michael Halstead replicate the controlled growth he pulled off at Intra-Cellular Therapies in mental health’s psychedelic era?

The market seems to have its pharma giants ranked in a peculiar order, leaving one of the group's fastest-growing performers trading at a middle-of-the-pack multiple rather than the group high.